The approval will enable the treatment of patients in India living with Essential Tremor, Tremor-dominant Parkinson’s Disease and neuropathic pain
Insightec, a global healthcare company focussed on transforming patient care, has received market approval from the Central Drugs Standard Control Organization (CDSCO) for its incision-less neurosurgery platform, the Exablate 4000.
The Exablate 4000 (Exablate Neuro) platform uses MR-guided focussed ultrasound to precisely ablate a small target deep within the brain without incisions. The approval will enable the treatment of patients in India living with Essential Tremor, Tremor-dominant Parkinson’s Disease and neuropathic pain.
“This approval adds to the growing recognition of the value of Focused Ultrasound for global healthcare systems,” commented Maurice R Ferré MD, Insightec CEO and Chairman of the Board of Directors. “More importantly, expanded access to our technology is helping to transform the lives of people living with debilitating medical conditions.”
